Breaking Through Core Technical Barriers
Beoka Oxygen Concentrators Cover All Scenarios: Plateau, Portable, and Precision Oxygen Supply
In the oxygen concentrator industry, the true technical barriers do not lie in "whether oxygen can be produced," but rather in how to generate oxygen stably in extreme environments, how to deliver precise oxygen supply in mobile scenarios, and how to achieve efficient heat dissipation within limited volume. Beoka has developed unique solutions to address these technical challenges.
Technical Challenge I
Oxygen concentrators primarily utilize Pressure Swing Adsorption (PSA) technology, where molecular sieves adsorb nitrogen and release oxygen under pressure. However, in plateau regions (above 3,000 meters altitude), atmospheric pressure drops significantly and ambient oxygen content becomes scarce. Traditional oxygen concentrators face two critical issues: first, insufficient compressor intake leading to sharply reduced oxygen production efficiency; second, inability to accurately determine users' actual oxygen requirements.
Beoka's Solution: Adaptive Altitude Pulse Control
Beoka applied for an invention patent in 2022 and was granted it in 2025 (Patent No. CN115779209B), titled "Adaptive Height Control Method and Pulse Oxygen Concentrator," which directly addresses this challenge.
The core logic of this patent:
Real-time atmospheric pressure acquisition: Built-in barometric sensors continuously detect altitude changes;
Dynamic calculation of target oxygen flow rate: Algorithms automatically determine required oxygen supply based on the differential between current and preset atmospheric pressure;
Precise pulse oxygen delivery: Controls concentrator output according to target flow rate.
Furthermore, select Beoka products employ American-imported bullet valve technology, ensuring stable oxygen concentration ≥90% at altitudes up to 5,000 meters and temperatures as low as -20°C—meeting medical-grade standards.
Technical Challenge II
Unlike continuous-flow oxygen devices, pulse-dose oxygen concentrators operate on the design principle of "delivering oxygen during inhalation, stopping during exhalation" to conserve oxygen and extend battery life. However, a core technical challenge exists: how to accurately identify the onset of user inhalation within milliseconds? If oxygen delivery lags, users experience "unable to breathe in"; if triggered prematurely or erroneously, oxygen is wasted. Traditional detection methods lack accuracy, resulting in poor user experience.
Beoka's Solution: Air Pressure Change Rate Detection Algorithm
Beoka's invention patent "Respiration Detection Method, Control Method for Pulse Oxygen Concentrator, and Pulse Oxygen Concentrator" (Patent No. CN114917440B), granted in October 2025, specifically tackles this challenge.
The innovations of this patent include:
l Real-time detection of gas pressure within the delivery channel, rather than relying solely on flow or temperature signals;
Calculation of pressure changes across multiple preset time intervals to form dynamic trend patterns;
Determination of respiratory status based on pressure change trends, precisely identifying inhalation onset;
Triggering pulse oxygen delivery only when the user is confirmed to be in inhalation state.
This technology "enables accurate detection of user respiration, thereby improving the accuracy of respiratory detection and oxygen delivery timing." Beoka's pulse-dose technology enhances oxygen utilization efficiency by over 30%—meaning longer device endurance with equivalent oxygen output, or lighter device weight with equivalent endurance requirements.
Technical Challenge III
The core contradiction in portable oxygen concentrators lies in this: reducing volume inevitably compresses heat dissipation space, yet compressor operation inevitably generates substantial heat. Poor thermal management leads to decreased efficiency, shortened lifespan, and even safety hazards from excessive compressor temperatures. Traditional oxygen concentrators rely on large-volume passive cooling, but portable devices cannot adopt this approach.
Beoka's Solution: Impeller-Integrated Active Cooling Technology
Beoka's utility model patent "Positive Displacement Single-Cylinder Air Compressor and Oxygen Concentrator" (Patent No. CN202320788317.0), granted in 2023, addresses the heat dissipation challenge at the compressor structure level.
The design breakthroughs of this patent include:
Direct integration of an impeller onto the rotating cylinder, rotating synchronously with the cylinder;
The impeller creates directional airflow from intake to exhaust ports within the housing during rotation;
Utilizing flowing air to actively remove heat generated by the rotating cylinder, rather than relying on passive radiation cooling.
The elegance of this design: no additional power source, no extra energy consumption—active air cooling achieved solely through the compressor's own rotational motion. The patent abstract states that this technology "can prevent adverse effects on the air compressor from long-term high-temperature operation," "reduces equipment operating temperature, extends air compressor service life, and improves oxygen concentrator portability and user comfort."
In actual products, this technology supports Beoka's lightweight target of reducing device weight to 1.5kg–1.8kg. Compared to traditional home oxygen concentrators typically exceeding 10kg, this breakthrough delivers significant engineering value.
Technical Challenge Ⅳ
The pain points for portable oxygen concentrator users are highly concentrated: the device must be both lightweight and long-lasting. However, battery weight is directly proportional to capacity. Achieving maximum endurance within limited weight presents a dual challenge in materials science and structural engineering.
Beoka's Solution: Modular Dual-Battery Design
At the energy level, the Beoka Portable Oxygen Concentrator PMO2-A adopts a modular dual-battery design, utilizing Tianjin Lishen Grade-A 3C power batteries (5,000mAh per unit). In Mode 1, the dual batteries provide approximately 360 minutes (6 hours) of endurance; even in Mode 5 high-flow mode, battery life exceeds 130 minutes. The batteries feature a detachable design, allowing users to carry spare batteries for rotation use, effectively resolving the conflict between single-use duration and device weight.
Technical Challenge V
How to achieve effective oxygen generation within a volume as small as a cup? How to ensure sufficient battery life and oxygen concentration while keeping the device lightweight (approx. 500g for the whole unit)? How to deliver precise oxygen supplementation with each inhalation in intermittent mode?
Beoka’s solution: micro PSA module + three stage concentration optimization
The M6 integrates a customized micro PSA oxygen generation system. By optimizing the molecular sieve packing density and airflow path, it achieves a maximum oxygen concentration of ≥80% (M1 mode) within a compact size of just 66×66×228 mm. Three modes are provided for different usage scenarios:
M1 intermittent mode: oxygen concentration ≥80%, delivers approx. 0.1L of nearly pure oxygen per press – suitable for rapid oxygen replenishment after high-intensity exercise.
M2 continuous mode: oxygen concentration ≥50%, flow rate 0.2 L/min – suitable for daily fatigue recovery or mild altitude adaptation.
M3 continuous mode: oxygen concentration ≥30%, flow rate 0.4 L/min – suitable for long-duration, low-intensity oxygen supplementation.
| Battery Spec | Weight | Battery life in M2/M3 continuous modes | M1 intermittent mode (presses) |
| 1600 mAh | 200g | approx. 90 minutes | approx. 30 cans (300 presses) |
| 2400 mAh | 300g | approx. 120 minutes | approx. 40 cans (400 presses) |
| 4000 mAh | 450g | approx. 210 minutes | approx. 70 cans (700 presses) |
Users can swap batteries according to trip duration without waiting for charging. The M6 also supports three recharging methods: PD 35W adapter, car charger, and power bank – it can be used while charging. The main unit weighs only about 500g, and with its ergonomic cup shaped design, it truly enables “burden free oxygen supplementation.”
